The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2023

Filed:

Feb. 24, 2022
Applicant:

Imedisync, Inc., Seoul, KR;

Inventors:

Seung Wan Kang, Seoul, KR;

Ukeob Park, Seoul, KR;

Ju Hee Ko, Seongnam-si, KR;

Namheon Kim, Paju-si, KR;

Tae-gyun Jeong, Seoul, KR;

Hyerin Jeong, Seoul, KR;

Assignee:

IMEDISYNC, INC., Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61B 5/00 (2006.01); A61B 5/369 (2021.01); G16H 10/60 (2018.01); G16H 50/70 (2018.01); G16H 50/20 (2018.01); A61B 5/374 (2021.01);
U.S. Cl.
CPC ...
A61B 5/4088 (2013.01); A61B 5/369 (2021.01); A61B 5/374 (2021.01); A61B 5/7264 (2013.01); A61B 5/7275 (2013.01); G16H 10/60 (2018.01); G16H 50/20 (2018.01); G16H 50/70 (2018.01); A61B 2576/026 (2013.01);
Abstract

Provided is a method for classifying severe cognitive impairment patients by analyzing electroencephalogram (EEG) data. The method of classifying severe cognitive impairment patients by analyzing EEG data includes a brainwave collection step of collecting EEG data on a plurality of users, a first classification step of classifying the plurality of users into a severe cognitive impairment group or a non-severe cognitive impairment group by analyzing the collected EEG data, a second classification step of classifying users included in the non-severe cognitive impairment group into a normal group or an amnestic mild cognitive impairment (aMCI) group, and a third classification group of classifying users included in the normal group into a within normal limits (WNL) group or a preclinical Alzheimer's disease (AD) group and classifying users included in the aMCI group into a non-AD MCI group or a prodromal AD group.


Find Patent Forward Citations

Loading…